Carlos Bais - Inhibrx Executive Sciences
| INBX Stock | USD 16.17 0.12 0.75% |
Executive
Carlos Bais is Executive Sciences of Inhibrx
| Address | 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037 |
| Phone | 858-795-4220 |
| Web | https://inhibrx.com |
Inhibrx Management Efficiency
The company has return on total asset (ROA) of (0.5746) % which means that it has lost $0.5746 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.3105) %, meaning that it created substantial loss on money invested by shareholders. Inhibrx's management efficiency ratios could be used to measure how well Inhibrx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.82 in 2024. Return On Capital Employed is likely to drop to -0.91 in 2024. At this time, Inhibrx's Net Tangible Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 22.7 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 9.9 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MD MA | Opthea | N/A | |
| Philip JD | Monte Rosa Therapeutics | 45 | |
| Mustapha Parekh | Design Therapeutics | N/A | |
| Jonathan JD | Stoke Therapeutics | 34 | |
| John Jordan | Viridian Therapeutics | N/A | |
| Huw Nash | Stoke Therapeutics | 57 | |
| Jennifer Johansson | Larimar Therapeutics | N/A | |
| Gayathri Diwakar | Crinetics Pharmaceuticals | N/A | |
| Matthew Gosling | Protagonist Therapeutics | 53 | |
| Mohammad Masjedizadeh | Protagonist Therapeutics | N/A | |
| Thomas Leggett | Stoke Therapeutics | 47 | |
| PharmD MS | Opthea | 52 | |
| Margaux Bennett | Kronos Bio | N/A | |
| Shannon Campbell | Merus BV | N/A | |
| Anthony Casicano | Viridian Therapeutics | 47 | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| Caroline MD | Ikena Oncology | 52 | |
| Carter King | Protagonist Therapeutics | 53 | |
| Gopi MBA | Larimar Therapeutics | 53 | |
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| Sandra Gardiner | Kronos Bio | 58 | |
Management Performance
| Return On Equity | -20.31 | ||||
| Return On Asset | -0.57 |
Inhibrx Leadership Team
Elected by the shareholders, the Inhibrx's board of directors comprises two types of representatives: Inhibrx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inhibrx. The board's role is to monitor Inhibrx's management team and ensure that shareholders' interests are well served. Inhibrx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inhibrx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Lappe, Chairman, Founder | ||
| Charbel PharmD, Vice Planning | ||
| Leah JD, Corporate VP | ||
| BS CPA, Chief Officer | ||
| Jeffrey Jensen, Executive Officer | ||
| Brendan Eckelman, Executive Officer | ||
| Carlos Bais, Executive Sciences | ||
| Josep Garcia, Executive Officer | ||
| Ashraf Amanullah, Executive Officer | ||
| David MBA, Executive Officer | ||
| Quinn Deveraux, Founder |
Inhibrx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Inhibrx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -20.31 | ||||
| Return On Asset | -0.57 | ||||
| Profit Margin | 1,020 % | ||||
| Current Valuation | 7.65 M | ||||
| Shares Outstanding | 14.48 M | ||||
| Shares Owned By Insiders | 23.54 % | ||||
| Shares Owned By Institutions | 68.09 % | ||||
| Number Of Shares Shorted | 742.52 K | ||||
| Price To Book | 1.06 X | ||||
| Price To Sales | 138.75 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| AVAV | AeroVironment | |
| ELVN | Enliven Therapeutics | |
| NFLX | Netflix |
Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.